Carbon ion radiotherapy for treatment of prostate cancer and subsequent outcomes after biochemical failure

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5105-5112

  Shimazaki, Jun ^a,b   Tsuji, Hiroshi ^a   Hitoshi, Ishikawa ^a   Okada, Tohru ^a   Akakura, Koichiro ^b   Suzuki, Hiroyoshi ^b   Harada, Masaoki ^c   Tsujii, Hirohiko ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

Carbon radiotherapy; External beam radiation therapy; Prostate cancer; PSA doubling time

Indexed keywords

BICALUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; ION THERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARBON RADIOISOTOPES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HEAVY IONS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78751487506     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cancer Control and Information Services, National Cancer Centre, Japan, http://www.ganjoho.jp/ 2008
2. Tsuji H, Yanagi T, Ishikawa H, Kamada T, Mizoe J-E, Kanai T, Morita S. Tsujii H and Working Group for Genitourinary Tumors: Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 63: 1153-1160. 2005
3. Akakura K, Tsujii H, Morita S, Tsuji H, Yagishita T, Isaka S, Ito H, Akaza H, Hata H, Fujime M, Harada M, Shimazaki J and Working Group for Genitourinary Tumors: Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58: 252-258. 2004.
4. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe J-E, Kanai T, Morita S, Wakatsuki M, Shimazaki J, Tsujii H and Working Group for Genitourinary Tumors: Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study. Radiother Oncol 81: 57-64, 2006
5. NCCN Clinical Practice Guidelines in Oncology V2, 2010
6. Cox JD, Stetz J and Pajak TF; Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiât Oncol Biol Phys 31: 1341-1346 1995.
7. Roach III M, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH and Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiât Oncol Biol Phys 65: 965-74 2006.
8. Schmid H-P, McNeal JE and Stamy TA: Observations on the doubling time of prostate cancer, the use of serial prostatespecific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71: 2031-2040, 1993.
9. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A and Keane PF: Methods of calculating prostate-specific antigen velocity. Eur Urol 52: 1044-1051, 2007 (Pubitemid 47332018)
10. Nakamura K, Teshima T, Takahashi Y, Imai A, Koizumi M, Mitsuhashi N, Inoue T and Japanese PCS Working Subgroup of Prostate Cancer: Radical radiation therapy for prostate cancer in Japan: a patterns of care study report. Jpn J Clin Oncol 33: 122-126, 2003.
11. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomazewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974, 1998. (Pubitemid 28445094)
12. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carison TP and Klein EA: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥ 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiât Oncol Biol phys 58: 25-33, 2004 (Pubitemid 38010333)
13. Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, Bonffrer JMG, Incrocci L and Lebesque JV: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24: 1990-1996, 2006.
14. Liauw SL, Stadler WM, Correa D, Weichselbaum RR and Jáni AB: Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiol Oncol Biol Phys 77: 125-130, 2010.
15. Talcott JA, Rossi C, Shipley WU, Slater JD, Niemierko A and Zietman AL: Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 303: 1046-1053, 2010.
16. Aizer AA, Yu JB, McKeon AM, Decker RH, Colberg JW and Peschel RE: Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 75: 1344-1349, 2009.
17. Jereczek-Fossa BA and Orecchia R: Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for nonmetastatic prostate cancer. Radiother Oncol 84: 197-215, 2007.
18. Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W and Slater JM: Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiât Oncol Biol Phy 59: 348-352, 2004. (Pubitemid 38622585)
19. Kanai T, Endo M, Minohara S, Miyahara N, Koyama-Ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T, Furusawa Y, Ando K, Suzuki M, Soga F and Kawachi K: Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiât Oncol Biol Phys 44: 201-210, 1999.
20. Ishikawa H, Tsuji H, Kamada T, Hirasawa N, Yanagi T, Mizoe JE, Akakura K, Suzuki H, Shimazaki J and Tsujii H; Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiât Oncol Biol Phys 66: 1084-1091, 2006.
21. Schutz FAB and Oh WK: Neoadjuvant and adjuvant therapies in prostate cancer. Urol Clin N Am 37: 97-104, 2010.
22. Roach III M, Bae K, Speight J, Wolkov HB, Rubin P, Lee J, Lawton C, Valicenti R, Grignon D and Pilepich MV: Short-term neoadjuvant androgen-deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26: 585-591, 2008. (Pubitemid 351264352)
23. Souhami L, Bae K, Pilepiich M and Sandler H: Impact of the duration of adjuvant hormone therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 27: 2137-2143, 2009.
24. Bolla M, de Rreijke TM, van Tienhoven G, van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Plerart M, Mauer ME, Collette L and EORTC Radiation Oncology Group and Genito-urinary Tract Cancer Group: Duration of androgen suppression in the treatment of prostate cancer. New Engl J Med 560: 2516-2527, 2009.
25. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnaro P, Terzoll E, Cognetti F and Carlini P: Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. Cancer 115: 3446-3456, 2009.
26. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM and Shipley WU: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21: 3972-3978, 2003. (Pubitemid 46606211)
27. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM and Shipley W: Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26: 2497-2504, 2008.
28. Arcangeli G, Strigari L, Arcangeli S, Petrongari MG, Saracino B, Gomellini S, Papalia R, Simone G, De Carli P and Gallucci M: Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int J Radiât Oncol Biol Phys 75: 975-982, 2009.
29. Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, Vickers A and Scardino PT: Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28: 1508-1513,2010.
30. Taylor LG, Canfield SE and Du XL: Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115: 2388-2399, 2009.
31. Krauss D, Kestin L, Ye H, Brabbins D, Ghilezan M, Gustafson G, Vicini F and Martinez A: Lack of benefit for the addition of androgen-deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiât Oncol Biol Phys. [doi 10.1016/ijrobp.2010. 04.004 epub]
32. Lawton CA, Bae K, Pilepich M, Hanks G and Shipley W: Longterm treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiât Oncol Biol Phys 70: 437-441,2008.
33. Souhami L, Bae K, Pilepich M and Sandler H: Timing of salvage hormone therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of radiation therapy oncology group 85-31. Int J Radat. Oncol Biol Phys. [doi 10.1016/ijrobp.2009.10.007 epub]
34. Buyyounouski MK, Hanlon AL, Horwitz EM and Pollack A: Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiât Oncol Biol Phys 70: 59-66, 2008.
35. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG and Pollack A: Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer 110: 68-80, 2007.
36. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP and Zattoni F: EAU Guidelines on prostate cancer. Eur Urol 53: 68-80, 2008.
37. Prout-Lima C, Taylor JMG, Williams SG, Ankerst DP, Liu N, Kestin LL, Bae K and Sandler HM: Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiât Oncol Biol Phys 72: 782-791, 2008.
38. Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Tai K-H, Spry NA, Gleeson PS and D'Esté C: Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115: 4477-4487, 2009.
39. Roach III M, Waldman F and Pollack A: Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 115 (13 suppl): 3112-3120, 2009.